Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
sIPV (JNJ-64152348) in Healthy Adults
NCT03032588Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2017
- Primary completion
- May 2018
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in poliomyelitis (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Number of Participants With Solicited Local Adverse Events at Day 8, Number of Participants With Solicited Systemic Adverse Events at Day 8 and 2 more. Started Oct 2017; status: completed.
02
Conditions
poliomyelitis
Beyond the preview
Go deeper on NCT03032588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03032588.